ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

NCS Group Asks DRG Adjustments For Institutions With Peer reviewed Components, 25 Protocol Patients

July 1, 1983

Funding Opportunities Listed (12-page issue).

July 11, 2003

CHOP Evaluation Plan In Jan. 22 Issue

January 15, 1982

Fisher, Bonadonna Studies Still Fuel DeVita’s Optimism; Carbon Lists Six Basic Research Needs

July 15, 1977

NCAB Subcommittee Suggests Comp Centers Must Have Core Grants

September 22, 1978

NCI Supercomputer Operations To Start In April

November 15, 1985